Diamedica Inc (DMCAF) 0.1700 $DMCAF
DiaMedica Announces U.S. Composition of Matter Patent for DM199
Marketwired - Tue Jun 14, 7:03AM CDT
MINNEAPOLIS, MINNESOTA--(Marketwired - Jun 14, 2016) - DiaMedica Inc. (the "Company"
(TSX VENTURE
MA)(OTCQB MCAF), today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9364521, entitled "Human Tissue Kallikrein 1 Glycosylation Isoforms". This patent contains claims that cover the composition of matter of DiaMedica's product candidate, DM199, and pharmaceutical compositions comprising DM199. The patent protects key composition of matter of DM199's proprietary recombinant kallikrein. DiaMedica is currently developing DM199 for the treatment of neurological and kidney diseases, with the focus on acute ischemic stroke and diabetic kidney disease. The patent has an expiration date of 2033, which does not include any potential patent term extension.
DMA.VN: 0.240 (+0.020)
DiaMedica Appoints Dr. Todd Verdoorn as Chief Scientific Officer
Marketwired - Mon May 09, 7:02AM CDT
MINNEAPOLIS, MINNESOTA--(Marketwired - May 9, 2016) - DiaMedica Inc. (the "Company" (TSX VENTURE MA)(OTCQB MCAF) today announced the appointment of Dr. Todd Verdoorn as the Company's Chief Scientific Officer.
DMA.VN: 0.240 (+0.020)
DiaMedica Completes Issue of Shares for Debt to BFC Group
Marketwired - Thu Apr 28, 7:02AM CDT
DiaMedica Inc. (the "Company" (TSX VENTURE: DMA)(OTCQB: DMCAF), announces the completion of the issuance of shares in settlement of a debt owed to the BFC Group, as announced on March 10, 2016 and as approved by the TSX Venture Exchange. The debt was incurred pursuant to consulting services provided by the BFC Group to the Company, including advising the Company as it considers establishing its presence and potential development partnerships with pharmaceutical firms in Asia.
DMA.VN: 0.240 (+0.020)
DiaMedica Announces Continuance Under the Canada Business Corporations Act
Marketwired - Mon Apr 18, 5:01PM CDT
DiaMedica Inc. (the "Company" (TSX VENTURE: DMA) (OTCQB: DMCAF), is pleased to announce that, effective April 11, 2016, it has been continued as a federal corporation subject to the provisions of the Canada Business Corporations Act. The continuance was approved by the shareholders of the Company at the Company's Annual General and Special Meeting of shareholders held on October 23, 2015.
DMA.VN: 0.240 (+0.020)
DiaMedica to Present at the 2016 BFC Global Healthcare Business Development and Investment Conference
Marketwired - Mon Apr 11, 10:27AM CDT
DiaMedica Inc. (TSX VENTURE: DMA)(OTCQB: DMCAF) (the "Company" , today announced that the Company will be presenting at the 2016 BFC Global Healthcare Business Development and Investment Conference taking place April 13th to 15th at the Marriott Hotel City Centre in Shanghai, China.
DMA.VN: 0.240 (+0.020)
DiaMedica Announces Issue of Shares for Services
Marketwired - Thu Mar 10, 7:02AM CST
DiaMedica Inc. (the "Company" (TSX VENTURE: DMA)(OTCQB: DMCAF), announces its intention to issue 50,000 shares at a deemed price of $0.20 to BFC Group for business development advisory services in lieu of cash.
DMA.VN: 0.240 (+0.020)
Global Hypertension Pipeline Review 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vln7pk/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertensionand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HypertensionOverview - Therapeutics Development - Pipeline Products for Hypertension - Overview - Pipeline Products for Hypertension - Comparative Analysis - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Carolus Therapeutics, Inc. - Cellceutix Corporation - DiaMedica Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Innopharmax Inc. - Insmed Incorporated - IntelGenx Corp. - Intercept Pharmaceuticals, Inc. - Ionis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - JW Pharmaceutical Corporation - Kowa Company, Ltd. - Lacer, S.A. - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Novartis AG - Noxamet Ltd - Omeros Corporation - Ono Pharmaceutical Co., Ltd. - Peloton Therapeutics, Inc. - Pfizer Inc. - Sihuan Pharmaceutical Holdings Group Ltd. - Silence Therapeutics Plc - VBS Pharmaceuticals - Vectura Group Plc - VG Life Sciences, Inc. - Vicore Pharma AB - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/vl...pertension
INSM: 9.92 (-0.37), PFE: 34.25 (-0.50), OMER: 10.84 (-0.14), ICPT: 140.11 (-1.47), ABBV: 59.84 (-1.06), IONS: 22.61 (-0.71), NVS: 78.02 (+1.13)
Stroke - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/23dsxv/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Stroke Overview - Therapeutics Development - Pipeline Products for Stroke - Overview - Pipeline Products for Stroke - Comparative Analysis - Stroke - Therapeutics under Development by Companies - Stroke - Therapeutics under Investigation by Universities/Institutes - Stroke - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Stroke - Products under Development by Companies - Stroke - Products under Investigation by Universities/Institutes - Stroke - Companies Involved in Therapeutics Development Companies Mentioned Include: - AB Science SA - Acorda Therapeutics, Inc. - Acticor Biotech - Biogen, Inc. - BioTime, Inc. - Cardax Pharmaceuticals, Inc. - Cellular Biomedicine Group, Inc. - CHA Bio & Diostech Co., Ltd. - CoDa Therapeutics, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - NoNO, Inc. - Omeros Corporation - Panacea Pharmaceuticals, Inc. - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Phoenix Biotechnology, Inc. - Phylogica Limited - PhytoHealth Corporation - Pozen, Inc. - Primary Peptides, Inc. - (Others) For more information visit http://www.researchandmarkets.com/research/23...e_pipeline
ACOR: 25.71 (-0.06), POZN: 5.94 (-0.43), CBMG: 15.28 (+0.04), OMER: 10.84 (-0.14)
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 73.76 (-0.49), BIOD: 0.32 (unch), CLBS: 0.50 (unch), ARGS: 5.64 (-0.16), AZN: 27.57 (-0.06), CGEN: 6.51 (-0.09), ATHX: 2.16 (-0.03)
DiaMedica Announces Non-Brokered Private Placement
Marketwired - Fri Feb 05, 2:47PM CST
DiaMedica Inc. (the "Company" (TSX VENTURE: DMA)(OTCQB: DMCAF), announces that, subject to TSX Venture Exchange ("TSXV" approval, it is undertaking a non-brokered private placement of up to 4,687,500 Units in the capital of the Company at an issue of $0.16 per Unit for gross proceeds of up to $750,000 (the "Offering" . Each Unit will consist of one common share in the capital of the Company (each a "Common Share" and one-half Common Share purchase warrant (each whole warrant, a "Warrant" , with each Warrant entitling the holder thereof to acquire an additional Common Share at an exercise price of $0.25 per Common Share prior to the expiry date that is two years after the date of issuance. All of the Units issued in connection with the Offering will be subject to a restricted period that expires four months after the issuance date.
DMA.VN: 0.240 (+0.020)
DiaMedica Provides Update on DM199 Opportunity in South East Asia
Marketwired - Tue Feb 02, 7:02AM CST
DiaMedica Inc. (TSX VENTURE: DMA)(OTCQB: DMCAF) (the "Company" a clinical-stage biotechnology company focused on developing novel protein therapeutics for vascular diseases, including stroke, today provides a corporate development update.
DMA.VN: 0.240 (+0.020)
DiaMedica Appoints Dr. Todd Verdoorn as Vice President of Neuroscience
Marketwired - Wed Jan 20, 3:01PM CST
DiaMedica Inc. (TSX VENTURE: DMA)(OTCQB: DMCAF) ("DiaMedica" , today announced the appointment of Dr. Todd Verdoorn as DiaMedica's Vice President of Neuroscience. Dr. Verdoorn has more than 26 years of experience working with both public and private companies to develop new treatments for neurological diseases, including five years working with Bristol-Myers Squibb's stroke group.
DMA.VN: 0.240 (+0.020)
DiaMedica Issues Stock Option Grant
Marketwired - Wed Dec 02, 4:01PM CST
DiaMedica Inc. (TSX VENTURE: DMA)(OTCQB: DMCAF), announces that the Board of Directors has granted options to purchase 2,694,000 common shares of the Corporation to the Company's management, directors and staff at an exercise price of $0.15 per share. These options were awarded in accordance with the Company's stock option plan for a ten-year term. A portion of the option issuance is in lieu of cash compensation.
DMA.VN: 0.240 (+0.020)
DiaMedica Announces U.S. Composition of Matter Patent for DM199
Marketwired - Tue Jun 14, 7:03AM CDT
MINNEAPOLIS, MINNESOTA--(Marketwired - Jun 14, 2016) - DiaMedica Inc. (the "Company"
(TSX VENTURE MA)(OTCQB MCAF), today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9364521, entitled "Human Tissue Kallikrein 1 Glycosylation Isoforms". This patent contains claims that cover the composition of matter of DiaMedica's product candidate, DM199, and pharmaceutical compositions comprising DM199. The patent protects key composition of matter of DM199's proprietary recombinant kallikrein. DiaMedica is currently developing DM199 for the treatment of neurological and kidney diseases, with the focus on acute ischemic stroke and diabetic kidney disease. The patent has an expiration date of 2033, which does not include any potential patent term extension. DMA.VN: 0.240 (+0.020)
DiaMedica Appoints Dr. Todd Verdoorn as Chief Scientific Officer
Marketwired - Mon May 09, 7:02AM CDT
MINNEAPOLIS, MINNESOTA--(Marketwired - May 9, 2016) - DiaMedica Inc. (the "Company"
(TSX VENTURE MA)(OTCQB MCAF) today announced the appointment of Dr. Todd Verdoorn as the Company's Chief Scientific Officer. DMA.VN: 0.240 (+0.020)
DiaMedica Completes Issue of Shares for Debt to BFC Group
Marketwired - Thu Apr 28, 7:02AM CDT
DiaMedica Inc. (the "Company"
(TSX VENTURE: DMA)(OTCQB: DMCAF), announces the completion of the issuance of shares in settlement of a debt owed to the BFC Group, as announced on March 10, 2016 and as approved by the TSX Venture Exchange. The debt was incurred pursuant to consulting services provided by the BFC Group to the Company, including advising the Company as it considers establishing its presence and potential development partnerships with pharmaceutical firms in Asia. DMA.VN: 0.240 (+0.020)
DiaMedica Announces Continuance Under the Canada Business Corporations Act
Marketwired - Mon Apr 18, 5:01PM CDT
DiaMedica Inc. (the "Company"
(TSX VENTURE: DMA) (OTCQB: DMCAF), is pleased to announce that, effective April 11, 2016, it has been continued as a federal corporation subject to the provisions of the Canada Business Corporations Act. The continuance was approved by the shareholders of the Company at the Company's Annual General and Special Meeting of shareholders held on October 23, 2015. DMA.VN: 0.240 (+0.020)
DiaMedica to Present at the 2016 BFC Global Healthcare Business Development and Investment Conference
Marketwired - Mon Apr 11, 10:27AM CDT
DiaMedica Inc. (TSX VENTURE: DMA)(OTCQB: DMCAF) (the "Company"
, today announced that the Company will be presenting at the 2016 BFC Global Healthcare Business Development and Investment Conference taking place April 13th to 15th at the Marriott Hotel City Centre in Shanghai, China. DMA.VN: 0.240 (+0.020)
DiaMedica Announces Issue of Shares for Services
Marketwired - Thu Mar 10, 7:02AM CST
DiaMedica Inc. (the "Company"
(TSX VENTURE: DMA)(OTCQB: DMCAF), announces its intention to issue 50,000 shares at a deemed price of $0.20 to BFC Group for business development advisory services in lieu of cash. DMA.VN: 0.240 (+0.020)
Global Hypertension Pipeline Review 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vln7pk/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertensionand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HypertensionOverview - Therapeutics Development - Pipeline Products for Hypertension - Overview - Pipeline Products for Hypertension - Comparative Analysis - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Carolus Therapeutics, Inc. - Cellceutix Corporation - DiaMedica Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Innopharmax Inc. - Insmed Incorporated - IntelGenx Corp. - Intercept Pharmaceuticals, Inc. - Ionis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - JW Pharmaceutical Corporation - Kowa Company, Ltd. - Lacer, S.A. - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Novartis AG - Noxamet Ltd - Omeros Corporation - Ono Pharmaceutical Co., Ltd. - Peloton Therapeutics, Inc. - Pfizer Inc. - Sihuan Pharmaceutical Holdings Group Ltd. - Silence Therapeutics Plc - VBS Pharmaceuticals - Vectura Group Plc - VG Life Sciences, Inc. - Vicore Pharma AB - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/vl...pertension
INSM: 9.92 (-0.37), PFE: 34.25 (-0.50), OMER: 10.84 (-0.14), ICPT: 140.11 (-1.47), ABBV: 59.84 (-1.06), IONS: 22.61 (-0.71), NVS: 78.02 (+1.13)
Stroke - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/23dsxv/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Stroke Overview - Therapeutics Development - Pipeline Products for Stroke - Overview - Pipeline Products for Stroke - Comparative Analysis - Stroke - Therapeutics under Development by Companies - Stroke - Therapeutics under Investigation by Universities/Institutes - Stroke - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Stroke - Products under Development by Companies - Stroke - Products under Investigation by Universities/Institutes - Stroke - Companies Involved in Therapeutics Development Companies Mentioned Include: - AB Science SA - Acorda Therapeutics, Inc. - Acticor Biotech - Biogen, Inc. - BioTime, Inc. - Cardax Pharmaceuticals, Inc. - Cellular Biomedicine Group, Inc. - CHA Bio & Diostech Co., Ltd. - CoDa Therapeutics, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - NoNO, Inc. - Omeros Corporation - Panacea Pharmaceuticals, Inc. - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Phoenix Biotechnology, Inc. - Phylogica Limited - PhytoHealth Corporation - Pozen, Inc. - Primary Peptides, Inc. - (Others) For more information visit http://www.researchandmarkets.com/research/23...e_pipeline
ACOR: 25.71 (-0.06), POZN: 5.94 (-0.43), CBMG: 15.28 (+0.04), OMER: 10.84 (-0.14)
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 73.76 (-0.49), BIOD: 0.32 (unch), CLBS: 0.50 (unch), ARGS: 5.64 (-0.16), AZN: 27.57 (-0.06), CGEN: 6.51 (-0.09), ATHX: 2.16 (-0.03)
DiaMedica Announces Non-Brokered Private Placement
Marketwired - Fri Feb 05, 2:47PM CST
DiaMedica Inc. (the "Company"
(TSX VENTURE: DMA)(OTCQB: DMCAF), announces that, subject to TSX Venture Exchange ("TSXV" approval, it is undertaking a non-brokered private placement of up to 4,687,500 Units in the capital of the Company at an issue of $0.16 per Unit for gross proceeds of up to $750,000 (the "Offering" . Each Unit will consist of one common share in the capital of the Company (each a "Common Share" and one-half Common Share purchase warrant (each whole warrant, a "Warrant" , with each Warrant entitling the holder thereof to acquire an additional Common Share at an exercise price of $0.25 per Common Share prior to the expiry date that is two years after the date of issuance. All of the Units issued in connection with the Offering will be subject to a restricted period that expires four months after the issuance date. DMA.VN: 0.240 (+0.020)
DiaMedica Provides Update on DM199 Opportunity in South East Asia
Marketwired - Tue Feb 02, 7:02AM CST
DiaMedica Inc. (TSX VENTURE: DMA)(OTCQB: DMCAF) (the "Company"
a clinical-stage biotechnology company focused on developing novel protein therapeutics for vascular diseases, including stroke, today provides a corporate development update. DMA.VN: 0.240 (+0.020)
DiaMedica Appoints Dr. Todd Verdoorn as Vice President of Neuroscience
Marketwired - Wed Jan 20, 3:01PM CST
DiaMedica Inc. (TSX VENTURE: DMA)(OTCQB: DMCAF) ("DiaMedica"
, today announced the appointment of Dr. Todd Verdoorn as DiaMedica's Vice President of Neuroscience. Dr. Verdoorn has more than 26 years of experience working with both public and private companies to develop new treatments for neurological diseases, including five years working with Bristol-Myers Squibb's stroke group. DMA.VN: 0.240 (+0.020)
DiaMedica Issues Stock Option Grant
Marketwired - Wed Dec 02, 4:01PM CST
DiaMedica Inc. (TSX VENTURE: DMA)(OTCQB: DMCAF), announces that the Board of Directors has granted options to purchase 2,694,000 common shares of the Corporation to the Company's management, directors and staff at an exercise price of $0.15 per share. These options were awarded in accordance with the Company's stock option plan for a ten-year term. A portion of the option issuance is in lieu of cash compensation.
DMA.VN: 0.240 (+0.020)
